AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.


BACKGROUND Drugs that block platelet-platelet and platelet-fibrin interactions via the alpha(IIb)beta(3) (glycoprotein IIb/IIIa) receptor are used daily in patients undergoing percutaneous coronary interventions. Along with expected increases in spontaneous bleeding, clinical trials have revealed a surprising increase in thrombosis when these drugs are used… (More)


  • Presentations referencing similar topics